IFNA2 and neoplasm: IGN002, an anti-CD20-IFNα fusion protein, consists of IFNα2b fused to C-terminus of the heavy chain of anti-CD20 via a short peptide linker, demonstrated greater antitumor activity in rituximab-resistant tumor models.